Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Trial Profile

Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Blinatumomab (Primary) ; Ponatinib (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Methotrexate
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2018 Planned End Date changed from 1 Nov 2024 to 1 Nov 2023.
    • 31 Aug 2018 Biomarkers information updated
    • 19 Mar 2018 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top